Skip to main content

Table 3 Changes in cardiopulmonary function of the participants after the 6-week intervention from baseline

From: Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study

 

control Group

Lower Dosage

Medium Dosage

High Dosage

Time P value

T × D P value

∆O2-pulse max (L/min/bpm)

0.73 (− 0.23, 1.68)

1.25 (0.23,2.27)

0.82 (0.07, 1.70)

1.17 (0.32, 2.02)

< 0.01

0.56

∆RER max

0.09 (0.00, 0.18)

−0.02 (− 0.07, 0.07)

0.05 (− 0.16, 0.11)

0.03 (− 0.08, 0.14)

0.04

0.36

∆ (L/min)

0.18 (0.02, 0.36)

0.23 (0.09,0.37)

0.26 (1.74, 0.35)

0.32 (0.20, 0.43)

< 0.01

0.48

∆ Peak power (Mets)

0.72 (−0.04, 1.49)

1.05 (0.45,1.65)

1.18 (0.78, 1.58)

1.45 (0.86, 2.06)

< 0.01

0.31

∆Peak workload (W)

10.9 (−2.47, 24.24)

11.25 (−0.43, 22.93)

13.58 (5.44, 21.7)

13.93 (8.92, 18.95)

< 0.01

0.58

∆HR@VT1 (bpm)

5.8& (0.3, , 11.4)

5.2& (1.1, 9.2)

12.8 (7.8, 17.8)

16.0 (10.4, 21.5)

< 0.01

< 0.01

∆O2-pulse @VT1 (L/min/bpm)

0.55 (−0.37, 1.46)

1.17 (0.71,1.62)

0.92 (0.17, 2.20)

2.00 (1.23, 2.77)

< 0.01

0.10

∆ @VT1 (L/min)

0.17#& (0.09, 0.24)

0.24& (0.18,0.30)

0.33 (0.25, 0.41)

0.47 (0.34, 0.60)

< 0.01

< 0.01

∆Power @AVT1 (Mets)

0.69#& (0.35, 1.03)

1.06& (0.80,1.31)

1.41& (1.02, 1.79)

2.13 (1.56, 2.69)

< 0.01

< 0.01

∆% @VT1 (%)

2.1& (−0.85, 1.49)

3.5& (0.05,7.00)

6.5 (3.62, 9.43)

10.3 (7.61,13.05)

< 0.01

< 0.01

∆HR@VT2 (bpm)

5.6 (1.9, 9.4)

6.7 (3.2, 10.2)

10.8 (4.5, 17.2)

12.4 (4.4, 20.5)

< 0.01

0.23

∆O2-pulse @VT2 (L/min/bpm)

0.55 (−0.37, 1.47)

1.58 (0.95,2.22)

0.50 (0.04, 1.91)

1.67 (0.72, 2.62)

< 0.01

0.16

∆ @VT2 (L/min)

0.20 (0.03, 1.49)

0.39 (0.26,0.52)

0.33 (0.22, 0.44)

0.44 (0.29, 0.58)

< 0.01

0.06

∆ Power @VT2 (Mets)

0.78 (0.07, 1.49)

1.78 (1.20,2.35)

1.56 (1.00, 2.11)

2.04 (1.34, 2.73)

< 0.01

0.03

∆% @VT2 (%)

1.55 (−1.75, 4.84)

6.67 (3.20,10.10)

4.25 (1.28, 7.22)

6.58 (3.57, 9.59)

< 0.01

0.06

∆O2/∆WR slope (ml/min/w)

0.11 (−0.58, 0.79)

0.44 (−0.16,1.04)

0.58 (0.01, 1.16)

0.69 (0.06, 1.45)

< 0.01

0.56

  1. Note: The difference of parameter between pre and post intervention among four groups were performed using one-way ANOVA. #VS medium dosage, P <  0.05, &VS large dosage, P <  0.05
  2. ANOVA for repeated measurement for interaction of time (T) and dose (D). bpm, beat per minute